Patrick Kelly Biography and Net Worth



Patrick joined Forma in 2016 and has over 20 years of experience leading translational clinical activities across a growing, early-stage portfolio of small molecule therapeutics. Patrick is the chief medical officer at Forma. Prior experiences in biopharma include vice president of clinical development for Infinity Pharmaceuticals, vice president of early development for Pfizer’s Oncology Business Unit and senior director of Wyeth Research. In his previous roles, Patrick contributed to the development of several approved products, including ReFacto AF® and BeneFIX® for the treatment of hemophilia, Bosulif® (bosutinib) for the treatment of chronic myelogenous leukemia, Daurisma® for the treatment of acute myelogenous leukemia, Besponsa® for the treatment of acute B-cell leukemia and Copiktra® for the treatment of chronic lymphocytic leukemia, small lymphocytic leukemia and follicular lymphoma. Patrick earned a Bachelor of Science degree in medicine from Loyola College and an M.D. from University of Maryland School of Medicine. He completed his internship and residency at New England Medical Center in Boston, followed by a pediatric hematology/oncology fellowship at Children’s Hospital in Oakland California. Patrick was a faculty member at St. Jude Children’s Research Hospital and at Cincinnati Children’s Hospital. Patrick has authored numerous original peer-reviewed reports as well as reviews, textbook chapters, editorial letters and original abstracts.

How do I contact Patrick F. Kelly?

The corporate mailing address for Dr. Kelly and other Forma Therapeutics executives is 500 ARSENAL STREET SUITE 100, WATERTOWN MA, 02472. Forma Therapeutics can also be reached via phone at 617-679-1970 and via email at [email protected]. Learn More on Patrick F. Kelly's contact information.

Has Patrick F. Kelly been buying or selling shares of Forma Therapeutics?

Patrick F. Kelly has not been actively trading shares of Forma Therapeutics during the last quarter. Most recently, Patrick F. Kelly sold 5,245 shares of the business's stock in a transaction on Wednesday, February 23rd. The shares were sold at an average price of $9.78, for a transaction totalling $51,296.10. Learn More on Patrick F. Kelly's trading history.

Who are Forma Therapeutics' active insiders?

Forma Therapeutics' insider roster includes Patrick Kelly (SVP), Frank Lee (CEO), Jeannette Potts (Insider), and Todd Shegog (CFO). Learn More on Forma Therapeutics' active insiders.

Patrick F. Kelly Insider Trading History at Forma Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/23/2022Sell5,245$9.78$51,296.10View SEC Filing Icon  
See Full Table

Patrick F. Kelly Buying and Selling Activity at Forma Therapeutics

This chart shows Patrick F Kelly's buying and selling at Forma Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Forma Therapeutics Company Overview

Forma Therapeutics logo
Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed/refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. Forma Therapeutics Holdings, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts. As of October 14, 2022, Forma Therapeutics Holdings, Inc. operates as a subsidiary of Novo Nordisk A/S.
Read More

Today's Range

Now: $20.01
Low: $20.01
High: $20.01

50 Day Range

MA: $20.00
Low: $19.91
High: $20.01

2 Week Range

Now: $20.01
Low: $4.95
High: $20.68

Volume

1 shs

Average Volume

847,595 shs

Market Capitalization

$957.54 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A